Stock comparison
BioMarin Pharmaceutical
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BMRN
BioMarin Pharmaceutical
Market cap
$10.45B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BMRN | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 58D | 69B | MTD |
| Benjamin Graham | 57D | 65B | MTD |
| Philip Fisher | 55C | 63C | MTD |
| Peter Lynch | 47D | 66B | MTD |
| Joel Greenblatt | 28F | 68B | MTD |
| Charlie Munger | 45D | 74B | MTD |
| Terry Smith | 52D | 70B | MTD |
Side-by-side metrics
| Metric | BMRN | MTD |
|---|---|---|
| Market cap | $10.45B | $22.29B |
| P/E (TTM) | 38.7x | 25.3x |
| EV/EBIT | 18.1x | 21.6x |
| ROIC (TTM) | 3.92% | 36.09% |
| Gross margin | 75.93% | 57.79% |
| Net margin | 8.29% | 21.4% |
| Revenue CAGR 5y | 14.93% | 2.01% |
| EPS CAGR 5y | 2.29% | 6.12% |
| Debt / Equity | 0.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BMRN leads on
- EPS CAGR 5y2.29%vs 6.12%+97%
- Revenue CAGR 5y14.93%vs 2.01%+87%
- Gross margin75.93%vs 57.79%+24%
- EV/EBIT18.1xvs 21.6x+16%
MTD leads on
- Debt / Equity-vs 0.2x+100%
- ROIC (TTM)36.09%vs 3.92%+89%
- Net margin21.4%vs 8.29%+61%
- Market cap$22.29Bvs $10.45B+53%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.